Evidence map›Paper›PMID 30976973›Full record

ArticleActa neuropathologica2019

Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes.

Juan F Reyes, Christopher Sackmann, Alana Hoffmann, Per Svenningsson, Jürgen Winkler, Martin Ingelsson, Martin Hallbeck

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Juan F ReyesDepartment of Clinical Pathology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. juan.reyes@liu.se.
Christopher SackmannDepartment of Clinical Pathology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Alana HoffmannDepartment of Molecular Neurology, University Hospital Erlangen, Erlangen, Germany.
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Jürgen WinklerDepartment of Molecular Neurology, University Hospital Erlangen, Erlangen, Germany.
Martin IngelssonSection of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Martin HallbeckDepartment of Clinical Pathology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. martin.hallbeck@liu.se.
Linköping University · SEUniversitätsklinikum Erlangen · DEKarolinska Institutet · SEUppsala University · SE

Funding

Vetenskapsrådet 523-2013-2735
6 · The paper itself

Abstract

The intercellular transfer of alpha-synuclein (α-syn) has been implicated in the progression of Parkinson's disease (PD) and multiple system atrophy (MSA). The cellular mechanisms underlying this process are now beginning to be elucidated. In this study, we demonstrate that the gap junction protein connexin-32 (Cx32) is centrally involved in the preferential uptake of α-syn oligomeric assemblies (oα-syn) in neurons and oligodendrocytes. In vitro, we demonstrate a clear correlation between Cx32 expression and oα-syn uptake. Pharmacological and genetic strategies targeting Cx32 successfully blocked oα-syn uptake. In cellular and transgenic mice modeling PD and MSA, we observed significant upregulation of Cx32 which correlates with α-syn accumulation. Notably, we could also demonstrate a direct interaction between α-syn and Cx32 in two out of four human PD cases that was absent in all four age-matched controls. These data are suggestive of a link between Cx32 and PD pathophysiology. Collectively, our results provide compelling evidence for Cx32 as a novel target for therapeutic intervention in PD and related α-synucleinopathies.

Indexed as

alpha-SynucleinAnimalsBrainConnexinsGap Junction beta-1 ProteinMiceMultiple System AtrophyNeuronsOligodendrogliaParkinson Diseasealpha-SynucleinConnexinsGap Junction beta-1 Proteinalpha-Synuclein (α-syn)Alzheimer’s disease (AD)Cell-to-cell transferCx32Gap junction proteinsGJB1Multiple system atrophy (MSA)Parkinson’s disease (PD)Prion-like transfer

Identifiers

PMID30976973
PMCPMC6570706
OpenAlexW2937030337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.